Review



mouse myoblast c2c12 cells  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC mouse myoblast c2c12 cells
    Transcriptomic analysis and GO enrichment of muscle cell differentiation following rADAMTS-1 treatment. <t>C2C12</t> cells were treated with 10 ng/ml rADAMTS-1 and differentiated for 3 days before RNA-seq analysis. (A) Volcano plot showing DEGs. Blue and red dots indicate significantly upregulated and downregulated DEGs, respectively. (B) Validation of selected DEGs from RNA-sequencing by quantitative PCR. Results are presented as mean ± SD. Statistical significance was determined using one-way analysis of variance with Tukey's post hoc test and is indicated as follows: * P<0.05 and ** P<0.01 vs. the control group. GO enrichment analysis of the top 20 terms associated with (C) Biological Process, (D) Cellular Component and (E) Molecular Function, based on the identified DEGs. GO, Gene Ontology; ADAMTS-1, a disintegrin and metalloproteinase with thrombospondin motifs 1; rADAMTS-1, recombinant ADAMTS-1; RNA-seq, RNA sequencing; DEG, differentially expressed genes.
    Mouse Myoblast C2c12 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 9151 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse myoblast c2c12 cells/product/ATCC
    Average 99 stars, based on 9151 article reviews
    mouse myoblast c2c12 cells - by Bioz Stars, 2026-02
    99/100 stars

    Images

    1) Product Images from "Recombinant ADAMTS-1 promotes muscle regeneration accompanied by downregulation of Notch signaling"

    Article Title: Recombinant ADAMTS-1 promotes muscle regeneration accompanied by downregulation of Notch signaling

    Journal: International Journal of Molecular Medicine

    doi: 10.3892/ijmm.2025.5718

    Transcriptomic analysis and GO enrichment of muscle cell differentiation following rADAMTS-1 treatment. C2C12 cells were treated with 10 ng/ml rADAMTS-1 and differentiated for 3 days before RNA-seq analysis. (A) Volcano plot showing DEGs. Blue and red dots indicate significantly upregulated and downregulated DEGs, respectively. (B) Validation of selected DEGs from RNA-sequencing by quantitative PCR. Results are presented as mean ± SD. Statistical significance was determined using one-way analysis of variance with Tukey's post hoc test and is indicated as follows: * P<0.05 and ** P<0.01 vs. the control group. GO enrichment analysis of the top 20 terms associated with (C) Biological Process, (D) Cellular Component and (E) Molecular Function, based on the identified DEGs. GO, Gene Ontology; ADAMTS-1, a disintegrin and metalloproteinase with thrombospondin motifs 1; rADAMTS-1, recombinant ADAMTS-1; RNA-seq, RNA sequencing; DEG, differentially expressed genes.
    Figure Legend Snippet: Transcriptomic analysis and GO enrichment of muscle cell differentiation following rADAMTS-1 treatment. C2C12 cells were treated with 10 ng/ml rADAMTS-1 and differentiated for 3 days before RNA-seq analysis. (A) Volcano plot showing DEGs. Blue and red dots indicate significantly upregulated and downregulated DEGs, respectively. (B) Validation of selected DEGs from RNA-sequencing by quantitative PCR. Results are presented as mean ± SD. Statistical significance was determined using one-way analysis of variance with Tukey's post hoc test and is indicated as follows: * P<0.05 and ** P<0.01 vs. the control group. GO enrichment analysis of the top 20 terms associated with (C) Biological Process, (D) Cellular Component and (E) Molecular Function, based on the identified DEGs. GO, Gene Ontology; ADAMTS-1, a disintegrin and metalloproteinase with thrombospondin motifs 1; rADAMTS-1, recombinant ADAMTS-1; RNA-seq, RNA sequencing; DEG, differentially expressed genes.

    Techniques Used: Cell Differentiation, RNA Sequencing, Biomarker Discovery, Real-time Polymerase Chain Reaction, Control, Recombinant



    Similar Products

    99
    ATCC mouse myoblast c2c12 cells
    Transcriptomic analysis and GO enrichment of muscle cell differentiation following rADAMTS-1 treatment. <t>C2C12</t> cells were treated with 10 ng/ml rADAMTS-1 and differentiated for 3 days before RNA-seq analysis. (A) Volcano plot showing DEGs. Blue and red dots indicate significantly upregulated and downregulated DEGs, respectively. (B) Validation of selected DEGs from RNA-sequencing by quantitative PCR. Results are presented as mean ± SD. Statistical significance was determined using one-way analysis of variance with Tukey's post hoc test and is indicated as follows: * P<0.05 and ** P<0.01 vs. the control group. GO enrichment analysis of the top 20 terms associated with (C) Biological Process, (D) Cellular Component and (E) Molecular Function, based on the identified DEGs. GO, Gene Ontology; ADAMTS-1, a disintegrin and metalloproteinase with thrombospondin motifs 1; rADAMTS-1, recombinant ADAMTS-1; RNA-seq, RNA sequencing; DEG, differentially expressed genes.
    Mouse Myoblast C2c12 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse myoblast c2c12 cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    mouse myoblast c2c12 cells - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC mouse skeletal muscle c2c12 cells
    Transcriptomic analysis and GO enrichment of muscle cell differentiation following rADAMTS-1 treatment. <t>C2C12</t> cells were treated with 10 ng/ml rADAMTS-1 and differentiated for 3 days before RNA-seq analysis. (A) Volcano plot showing DEGs. Blue and red dots indicate significantly upregulated and downregulated DEGs, respectively. (B) Validation of selected DEGs from RNA-sequencing by quantitative PCR. Results are presented as mean ± SD. Statistical significance was determined using one-way analysis of variance with Tukey's post hoc test and is indicated as follows: * P<0.05 and ** P<0.01 vs. the control group. GO enrichment analysis of the top 20 terms associated with (C) Biological Process, (D) Cellular Component and (E) Molecular Function, based on the identified DEGs. GO, Gene Ontology; ADAMTS-1, a disintegrin and metalloproteinase with thrombospondin motifs 1; rADAMTS-1, recombinant ADAMTS-1; RNA-seq, RNA sequencing; DEG, differentially expressed genes.
    Mouse Skeletal Muscle C2c12 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse skeletal muscle c2c12 cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    mouse skeletal muscle c2c12 cells - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC mouse myoblast cell line c2c12
    Transcriptomic analysis and GO enrichment of muscle cell differentiation following rADAMTS-1 treatment. <t>C2C12</t> cells were treated with 10 ng/ml rADAMTS-1 and differentiated for 3 days before RNA-seq analysis. (A) Volcano plot showing DEGs. Blue and red dots indicate significantly upregulated and downregulated DEGs, respectively. (B) Validation of selected DEGs from RNA-sequencing by quantitative PCR. Results are presented as mean ± SD. Statistical significance was determined using one-way analysis of variance with Tukey's post hoc test and is indicated as follows: * P<0.05 and ** P<0.01 vs. the control group. GO enrichment analysis of the top 20 terms associated with (C) Biological Process, (D) Cellular Component and (E) Molecular Function, based on the identified DEGs. GO, Gene Ontology; ADAMTS-1, a disintegrin and metalloproteinase with thrombospondin motifs 1; rADAMTS-1, recombinant ADAMTS-1; RNA-seq, RNA sequencing; DEG, differentially expressed genes.
    Mouse Myoblast Cell Line C2c12, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse myoblast cell line c2c12/product/ATCC
    Average 99 stars, based on 1 article reviews
    mouse myoblast cell line c2c12 - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC c2c12 mouse myoblast cell line
    ( A ) <t>C2C12</t> cells (n=5) were seeded in 24 well plates and co-transfected with Ψ modified mRNAs encoding luciferase (L) , GFP (G) and PR8S (P) at mass ratios L G P = 1 : (1−ε): ε (where ε is 0, 0.5 or 1) . 4 h after mRNA complexes were added, cells were treated with cytokines supplemented media at non-toxic concentrations IFN-β (50ng/mL), IL-1β (1ng/mL) or IL-6 (1ng/mL) for 18 h followed by luciferase assay. Cell viability of all groups were similar (Supplementary Figure S5). Results were normalized by luciferase expression of non-treated cells and reported as relative luciferase expression representing extent of translation inhibition by cytokines. Results were presented as the mean SEM. ( B ) C2C12 cells (n=5) were co-transfected with Ψ modified mRNAs encoding luciferase (L), IFN-α (I), GFP (G) and PR8S (P) at mass ratios L I G P = 2 : 1 : (1−ε): ε (where ε is 0, 0.5, 0.75 or 1). Control cells for each mass ratio were similarly transfected with G replacing I i.e. L G G P = 2 : 1: (1−ε) : ε. Luciferase expression was measured 18h later. Cell viability of all groups were similar (Supplementary Figure S5). Results were presented as the mean SEM. ( C ) C57Bl/6 Mice (n=8) were intramuscularly injected with 8 µg Luc mRNA, together with 8 µg GFP mRNA (Luc+GFP), 4 µg GFP mRNA + 4 µg IFN-α mRNA (Luc+GFP+IFN), 4 µg GFP mRNA + 4 µg PR8S mRNA (Luc+PR8S+GFP), or 4 µg PR8S mRNA + 4 µg IFN-α mRNA (Luc+PR8S+IFN). Non-treated (NT) group was injected with buffer without mRNA. Bioluminescence was assayed by IVIS 5 h after injection and once daily thereafter. Results were presented as the mean SEM. ( D ) C57Bl/6 Mice (n=4) were intramuscularly injected twice (7 days apart) with 8 µg OVA mRNA, together with either 8 µg GFP mRNA (OVA+GFP), 4 µg GFP mRNA + 4 µg IFN-α mRNA (OVA+GFP+IFN), 4 µg PR8S mRNA + 4 µg GFP mRNA (OVA+PR8S+GFP), 4 µg PR8S mRNA + 4 µg IFN-α mRNA (OVA+PR8S+IFN). Non-treated (NT) group was injected with buffer without mRNA. 7 days after the second injection, blood was collected by cardiac puncture and anti-OVA IgG titers were quantified by ELISA. Results were presented as the mean SEM with individual values shown.
    C2c12 Mouse Myoblast Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c2c12 mouse myoblast cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    c2c12 mouse myoblast cell line - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC mouse muscle cell line c2c12
    Differential glycan composition on Env expressed in different cell lines. Glycan composition at reporter glycosylation sites predominantly displaying: oligomannose-type glycans (N332), a mixture of complex- and oligomannose-type glycans (N355), and complex-type glycans (N88). Four different production systems were used as described in the key, including expression in three different cell lines, HEK293F, <t>C2C12</t> and DC2.4 cells. All the glycan composition observed in the site-specific analysis are shown on the left, simplified in distinct categories represented as, core, oligomannose-type, and complex-type glycans. Some compositions annotated as complex-type glycans can exhibit isomers formally constituting hybrid-type glycans. Represented glycan compositions (See Methods for full classification) are colored according to the scale provided in the right for each category of glycan composition. The representative glycan composition data at all the sites is the average of three or more biological replicates.
    Mouse Muscle Cell Line C2c12, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse muscle cell line c2c12/product/ATCC
    Average 99 stars, based on 1 article reviews
    mouse muscle cell line c2c12 - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC mouse myoblast cells
    Differential glycan composition on Env expressed in different cell lines. Glycan composition at reporter glycosylation sites predominantly displaying: oligomannose-type glycans (N332), a mixture of complex- and oligomannose-type glycans (N355), and complex-type glycans (N88). Four different production systems were used as described in the key, including expression in three different cell lines, HEK293F, <t>C2C12</t> and DC2.4 cells. All the glycan composition observed in the site-specific analysis are shown on the left, simplified in distinct categories represented as, core, oligomannose-type, and complex-type glycans. Some compositions annotated as complex-type glycans can exhibit isomers formally constituting hybrid-type glycans. Represented glycan compositions (See Methods for full classification) are colored according to the scale provided in the right for each category of glycan composition. The representative glycan composition data at all the sites is the average of three or more biological replicates.
    Mouse Myoblast Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse myoblast cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    mouse myoblast cells - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC mouse skeletal muscle myoblast cell line c2c12
    Differential glycan composition on Env expressed in different cell lines. Glycan composition at reporter glycosylation sites predominantly displaying: oligomannose-type glycans (N332), a mixture of complex- and oligomannose-type glycans (N355), and complex-type glycans (N88). Four different production systems were used as described in the key, including expression in three different cell lines, HEK293F, <t>C2C12</t> and DC2.4 cells. All the glycan composition observed in the site-specific analysis are shown on the left, simplified in distinct categories represented as, core, oligomannose-type, and complex-type glycans. Some compositions annotated as complex-type glycans can exhibit isomers formally constituting hybrid-type glycans. Represented glycan compositions (See Methods for full classification) are colored according to the scale provided in the right for each category of glycan composition. The representative glycan composition data at all the sites is the average of three or more biological replicates.
    Mouse Skeletal Muscle Myoblast Cell Line C2c12, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse skeletal muscle myoblast cell line c2c12/product/ATCC
    Average 99 stars, based on 1 article reviews
    mouse skeletal muscle myoblast cell line c2c12 - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    Image Search Results


    Transcriptomic analysis and GO enrichment of muscle cell differentiation following rADAMTS-1 treatment. C2C12 cells were treated with 10 ng/ml rADAMTS-1 and differentiated for 3 days before RNA-seq analysis. (A) Volcano plot showing DEGs. Blue and red dots indicate significantly upregulated and downregulated DEGs, respectively. (B) Validation of selected DEGs from RNA-sequencing by quantitative PCR. Results are presented as mean ± SD. Statistical significance was determined using one-way analysis of variance with Tukey's post hoc test and is indicated as follows: * P<0.05 and ** P<0.01 vs. the control group. GO enrichment analysis of the top 20 terms associated with (C) Biological Process, (D) Cellular Component and (E) Molecular Function, based on the identified DEGs. GO, Gene Ontology; ADAMTS-1, a disintegrin and metalloproteinase with thrombospondin motifs 1; rADAMTS-1, recombinant ADAMTS-1; RNA-seq, RNA sequencing; DEG, differentially expressed genes.

    Journal: International Journal of Molecular Medicine

    Article Title: Recombinant ADAMTS-1 promotes muscle regeneration accompanied by downregulation of Notch signaling

    doi: 10.3892/ijmm.2025.5718

    Figure Lengend Snippet: Transcriptomic analysis and GO enrichment of muscle cell differentiation following rADAMTS-1 treatment. C2C12 cells were treated with 10 ng/ml rADAMTS-1 and differentiated for 3 days before RNA-seq analysis. (A) Volcano plot showing DEGs. Blue and red dots indicate significantly upregulated and downregulated DEGs, respectively. (B) Validation of selected DEGs from RNA-sequencing by quantitative PCR. Results are presented as mean ± SD. Statistical significance was determined using one-way analysis of variance with Tukey's post hoc test and is indicated as follows: * P<0.05 and ** P<0.01 vs. the control group. GO enrichment analysis of the top 20 terms associated with (C) Biological Process, (D) Cellular Component and (E) Molecular Function, based on the identified DEGs. GO, Gene Ontology; ADAMTS-1, a disintegrin and metalloproteinase with thrombospondin motifs 1; rADAMTS-1, recombinant ADAMTS-1; RNA-seq, RNA sequencing; DEG, differentially expressed genes.

    Article Snippet: Mouse myoblast C2C12 cells (cat. no. CRL-1772; ATCC) were obtained from ATCC.

    Techniques: Cell Differentiation, RNA Sequencing, Biomarker Discovery, Real-time Polymerase Chain Reaction, Control, Recombinant

    ( A ) C2C12 cells (n=5) were seeded in 24 well plates and co-transfected with Ψ modified mRNAs encoding luciferase (L) , GFP (G) and PR8S (P) at mass ratios L G P = 1 : (1−ε): ε (where ε is 0, 0.5 or 1) . 4 h after mRNA complexes were added, cells were treated with cytokines supplemented media at non-toxic concentrations IFN-β (50ng/mL), IL-1β (1ng/mL) or IL-6 (1ng/mL) for 18 h followed by luciferase assay. Cell viability of all groups were similar (Supplementary Figure S5). Results were normalized by luciferase expression of non-treated cells and reported as relative luciferase expression representing extent of translation inhibition by cytokines. Results were presented as the mean SEM. ( B ) C2C12 cells (n=5) were co-transfected with Ψ modified mRNAs encoding luciferase (L), IFN-α (I), GFP (G) and PR8S (P) at mass ratios L I G P = 2 : 1 : (1−ε): ε (where ε is 0, 0.5, 0.75 or 1). Control cells for each mass ratio were similarly transfected with G replacing I i.e. L G G P = 2 : 1: (1−ε) : ε. Luciferase expression was measured 18h later. Cell viability of all groups were similar (Supplementary Figure S5). Results were presented as the mean SEM. ( C ) C57Bl/6 Mice (n=8) were intramuscularly injected with 8 µg Luc mRNA, together with 8 µg GFP mRNA (Luc+GFP), 4 µg GFP mRNA + 4 µg IFN-α mRNA (Luc+GFP+IFN), 4 µg GFP mRNA + 4 µg PR8S mRNA (Luc+PR8S+GFP), or 4 µg PR8S mRNA + 4 µg IFN-α mRNA (Luc+PR8S+IFN). Non-treated (NT) group was injected with buffer without mRNA. Bioluminescence was assayed by IVIS 5 h after injection and once daily thereafter. Results were presented as the mean SEM. ( D ) C57Bl/6 Mice (n=4) were intramuscularly injected twice (7 days apart) with 8 µg OVA mRNA, together with either 8 µg GFP mRNA (OVA+GFP), 4 µg GFP mRNA + 4 µg IFN-α mRNA (OVA+GFP+IFN), 4 µg PR8S mRNA + 4 µg GFP mRNA (OVA+PR8S+GFP), 4 µg PR8S mRNA + 4 µg IFN-α mRNA (OVA+PR8S+IFN). Non-treated (NT) group was injected with buffer without mRNA. 7 days after the second injection, blood was collected by cardiac puncture and anti-OVA IgG titers were quantified by ELISA. Results were presented as the mean SEM with individual values shown.

    Journal: Scientific Reports

    Article Title: Influenza A virus derived NS1 enhances translation of HPLC purified mRNA and interferon adjuvanted mRNA vaccination

    doi: 10.1038/s41598-026-35611-5

    Figure Lengend Snippet: ( A ) C2C12 cells (n=5) were seeded in 24 well plates and co-transfected with Ψ modified mRNAs encoding luciferase (L) , GFP (G) and PR8S (P) at mass ratios L G P = 1 : (1−ε): ε (where ε is 0, 0.5 or 1) . 4 h after mRNA complexes were added, cells were treated with cytokines supplemented media at non-toxic concentrations IFN-β (50ng/mL), IL-1β (1ng/mL) or IL-6 (1ng/mL) for 18 h followed by luciferase assay. Cell viability of all groups were similar (Supplementary Figure S5). Results were normalized by luciferase expression of non-treated cells and reported as relative luciferase expression representing extent of translation inhibition by cytokines. Results were presented as the mean SEM. ( B ) C2C12 cells (n=5) were co-transfected with Ψ modified mRNAs encoding luciferase (L), IFN-α (I), GFP (G) and PR8S (P) at mass ratios L I G P = 2 : 1 : (1−ε): ε (where ε is 0, 0.5, 0.75 or 1). Control cells for each mass ratio were similarly transfected with G replacing I i.e. L G G P = 2 : 1: (1−ε) : ε. Luciferase expression was measured 18h later. Cell viability of all groups were similar (Supplementary Figure S5). Results were presented as the mean SEM. ( C ) C57Bl/6 Mice (n=8) were intramuscularly injected with 8 µg Luc mRNA, together with 8 µg GFP mRNA (Luc+GFP), 4 µg GFP mRNA + 4 µg IFN-α mRNA (Luc+GFP+IFN), 4 µg GFP mRNA + 4 µg PR8S mRNA (Luc+PR8S+GFP), or 4 µg PR8S mRNA + 4 µg IFN-α mRNA (Luc+PR8S+IFN). Non-treated (NT) group was injected with buffer without mRNA. Bioluminescence was assayed by IVIS 5 h after injection and once daily thereafter. Results were presented as the mean SEM. ( D ) C57Bl/6 Mice (n=4) were intramuscularly injected twice (7 days apart) with 8 µg OVA mRNA, together with either 8 µg GFP mRNA (OVA+GFP), 4 µg GFP mRNA + 4 µg IFN-α mRNA (OVA+GFP+IFN), 4 µg PR8S mRNA + 4 µg GFP mRNA (OVA+PR8S+GFP), 4 µg PR8S mRNA + 4 µg IFN-α mRNA (OVA+PR8S+IFN). Non-treated (NT) group was injected with buffer without mRNA. 7 days after the second injection, blood was collected by cardiac puncture and anti-OVA IgG titers were quantified by ELISA. Results were presented as the mean SEM with individual values shown.

    Article Snippet: NIH-3T3 mouse fibroblasts, C2C12 mouse myoblast cell line and HepG2 liver cancer cells were purchased from the American Type Culture Collection (ATCC); NIH-3T3 cells were cultured in Dulbecco’s Modified Eagle Medium (Hyclone).

    Techniques: Transfection, Modification, Luciferase, Expressing, Inhibition, Control, Injection, Enzyme-linked Immunosorbent Assay

    Differential glycan composition on Env expressed in different cell lines. Glycan composition at reporter glycosylation sites predominantly displaying: oligomannose-type glycans (N332), a mixture of complex- and oligomannose-type glycans (N355), and complex-type glycans (N88). Four different production systems were used as described in the key, including expression in three different cell lines, HEK293F, C2C12 and DC2.4 cells. All the glycan composition observed in the site-specific analysis are shown on the left, simplified in distinct categories represented as, core, oligomannose-type, and complex-type glycans. Some compositions annotated as complex-type glycans can exhibit isomers formally constituting hybrid-type glycans. Represented glycan compositions (See Methods for full classification) are colored according to the scale provided in the right for each category of glycan composition. The representative glycan composition data at all the sites is the average of three or more biological replicates.

    Journal: RSC Chemical Biology

    Article Title: Signatures of native-like glycosylation in RNA replicon-derived HIV-1 immunogens

    doi: 10.1039/d5cb00165j

    Figure Lengend Snippet: Differential glycan composition on Env expressed in different cell lines. Glycan composition at reporter glycosylation sites predominantly displaying: oligomannose-type glycans (N332), a mixture of complex- and oligomannose-type glycans (N355), and complex-type glycans (N88). Four different production systems were used as described in the key, including expression in three different cell lines, HEK293F, C2C12 and DC2.4 cells. All the glycan composition observed in the site-specific analysis are shown on the left, simplified in distinct categories represented as, core, oligomannose-type, and complex-type glycans. Some compositions annotated as complex-type glycans can exhibit isomers formally constituting hybrid-type glycans. Represented glycan compositions (See Methods for full classification) are colored according to the scale provided in the right for each category of glycan composition. The representative glycan composition data at all the sites is the average of three or more biological replicates.

    Article Snippet: The mouse muscle cell line (C2C12) was cultured in Dulbecco's modified Eagles medium supplemented with 10% fetal bovine serum (FBS) as recommended in manufacturer's protocol (American type culture collection, Catalogue no. CRL-1772).

    Techniques: Glycoproteomics, Expressing